Australia & American Society of Clinical Oncology

Australia: Australia participated in the international OPTIMA trial, contributing to the global validation of the Prosigna test's effectiveness in breast cancer treatment.

American Society of Clinical Oncology: The American Society of Clinical Oncology is hosting its annual meeting where the groundbreaking results of the OPTIMA trial are being presented, disseminating the findings to a global audience of cancer specialists.

Australia: Australia was one of the nations where the study was conducted and where academic research groups contributed funding.

American Society of Clinical Oncology: The American Society of Clinical Oncology featured the study findings at its annual meeting, with its chief medical officer, Julie Gralow, endorsing the high quality of evidence presented.

Australia: Australia>>> is one of the countries where patients were enrolled for the KEYNOTE-942 trial, contributing to the global scope of the research. Its involvement highlights its participation in international medical studies.

American Society of Clinical Oncology: The American Society of Clinical Oncology>>> is hosting the presentation of the trial results, solidifying its role as a central platform for disseminating significant cancer research. This event enhances its prestige and influence within the oncology community.